The invention relates to novel antiviral active components of the general formula 1, pharmaceutical composition, antiviral medicament, method for prophylaxis and treatment of viral diseases, particularly caused by hepatisis C viruses (HCV). In the general formula 1R1 represents hydrogen, optionally substituted C1-C4 alkyl, C6 cycloalkyl, aryl, ethoxycarbonyl, nitro group R2 represents hydrogen R3 represents N-mono-or N,N-disubstituted 1-methylene-piperidine-3-carboxamide of the general formula 1a or N-mono- or N,N-disubstituted 1-methylene-piperidine-4-carboxamide of the general formula 1b R4 represents hydrogen, optionally substituted C1-C3 alkyl or R2 and R3 together with the C-atoms they are attached to form substituted ,3,4,9-tetrahydro-1H-carbazole of the general formula 1.1, or R2, R3, and R4 together with the atoms they are attached to form substituted azaheterocycles of the eneral formula 1.2 R5 and R6 optionally identical represent hydrogen, optionally substituted C1-C3 alkyl or C3-C6 cydoalkyl, or R5 and R6 together with the N-atom they are attached to form optionally substituted 5- or 6- membered azaheterocyclyl comprising one or two N-atoms and optionally condensed with benzene ringR7 and R8 represent hydrogen or R7 and R8 together with the C-atom they are attached to form C=O group R9 represents azaheterocyclyl comprising at least one N-atom, unsubstituted formamide, or phenyl substituted with ethoxycarbonyl or nitro group R10 represents hydrogen, optionally substituted C1-C3 alkyl, substituted acetyl n = 1 or 2 solid line accompanied by the dotted line, i.e. (), represents single or double C-C bond.
